In our study, we discovered a causal association between SGLT2 inhibition and a 1.8% increased risk of bladder cancer, a potential 0.4% elevated risk of small intestinal cancer, and a potential 1.1% reduced risk of rectal cancer. Here, SLC5A2 is linked to small intestine cancer.